NCT00576173View on ClinicalTrials.gov

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

February 28, 2007

Conditions
Pain
Interventions
DRUG

tramadol hydrochloride; acetaminophen

Sponsors
All Listed Sponsors
lead

Johnson & Johnson Taiwan Ltd

INDUSTRY